Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gentile

Showing results (291-300 of 313) with videos related to

Pageof 32
Sort By:
Haematologica|July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Leukemia & Lymphoma|April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Hematological Oncology|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Pageof 32

Showing results (291-300 of 313) with videos related to

Sort By:
Pageof 32
Haematologica|July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Leukemia & Lymphoma|April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Hematological Oncology|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Pageof 32